{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n\"Selectively binds\" or \"specifically binds\" means, for instance, that an antibody binds to a protein with a KD of about 0.1 mM or less, more usually about 1 pM or less.\n\"Selectively binds\" or \"specifically binds\" means at times that an antibody binds to a protein with a KD of about 0. 1 mM or less, at times about 1 pM or less, at times about 0. 1 pM or less, at times about 0.01 pM or less, and at times about 1 nM or less."}
{"final_json": [{"molecule_name": null, "protein_target_name": "protein", "binding_metric": "KD", "value": "0.1", "unit": "mM"}, {"molecule_name": null, "protein_target_name": "protein", "binding_metric": "KD", "value": "1", "unit": "pM"}, {"molecule_name": null, "protein_target_name": "protein", "binding_metric": "KD", "value": "0.1", "unit": "mM"}, {"molecule_name": null, "protein_target_name": "protein", "binding_metric": "KD", "value": "1", "unit": "pM"}, {"molecule_name": null, "protein_target_name": "protein", "binding_metric": "KD", "value": "0.1", "unit": "pM"}, {"molecule_name": null, "protein_target_name": "protein", "binding_metric": "KD", "value": "0.01", "unit": "pM"}, {"molecule_name": null, "protein_target_name": "protein", "binding_metric": "KD", "value": "1", "unit": "nM"}]}
{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nPonatinib inhibited the in vitro tyrosine kinase activity of ABL and T315I mutant ABL with IC 50 concentrations of 0.4 nM and 2.0 nM, respectively.\nPonatinib inhibited the in vitro activity of additional kinases with IC50 concentrations between 0.1 nM and 20 nM, including members of the VEGFR, PDGFR, FGFR, EPH receptors and SRC families of kinases, and KIT, RET. TIE2, and FLT3."}
{"final_json": [{"molecule_name": "Ponatinib", "protein_target_name": "ABL", "binding_metric": "IC50", "value": "0.4", "unit": "nM"}, {"molecule_name": "Ponatinib", "protein_target_name": "T315I mutant ABL", "binding_metric": "IC50", "value": "2.0", "unit": "nM"}, {"molecule_name": "Ponatinib", "protein_target_name": "VEGFR", "binding_metric": "IC50", "value": "0.1-20", "unit": "nM"}, {"molecule_name": "Ponatinib", "protein_target_name": "PDGFR", "binding_metric": "IC50", "value": "0.1-20", "unit": "nM"}, {"molecule_name": "Ponatinib", "protein_target_name": "FGFR", "binding_metric": "IC50", "value": "0.1-20", "unit": "nM"}, {"molecule_name": "Ponatinib", "protein_target_name": "EPH receptors", "binding_metric": "IC50", "value": "0.1-20", "unit": "nM"}, {"molecule_name": "Ponatinib", "protein_target_name": "SRC families of kinases", "binding_metric": "IC50", "value": "0.1-20", "unit": "nM"}, {"molecule_name": "Ponatinib", "protein_target_name": "KIT", "binding_metric": "IC50", "value": "0.1-20", "unit": "nM"}, {"molecule_name": "Ponatinib", "protein_target_name": "RET", "binding_metric": "IC50", "value": "0.1-20", "unit": "nM"}, {"molecule_name": "Ponatinib", "protein_target_name": "TIE2", "binding_metric": "IC50", "value": "0.1-20", "unit": "nM"}, {"molecule_name": "Ponatinib", "protein_target_name": "FLT3", "binding_metric": "IC50", "value": "0.1-20", "unit": "nM"}]}
{"raw_mentions": "Here are the extracted sentences:\n\nlarotrectinib inhibited TRKA, TRKB, and TRKC with IC50 values between 5-11 nM."}
{"final_json": [{"molecule_name": "larotrectinib", "protein_target_name": "TRKA", "binding_metric": "IC50", "value": "5-11", "unit": "nM"}, {"molecule_name": "larotrectinib", "protein_target_name": "TRKB", "binding_metric": "IC50", "value": "5-11", "unit": "nM"}, {"molecule_name": "larotrectinib", "protein_target_name": "TRKC", "binding_metric": "IC50", "value": "5-11", "unit": "nM"}]}
{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nThe apparent affinity' (KD) of ibritumomab tiuxetan for the CD20 antigen ranges between approximately 14 to 18 nM."}
{"final_json": [{"molecule_name": "ibritumomab tiuxetan", "protein_target_name": "CD20 antigen", "binding_metric": "KD", "value": "14 to 18", "unit": "nM"}]}
{"raw_mentions": "Vorinostat inhibits the enzymatic activity of histone deacety lases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50 &lt; 86 nM)."}
{"final_json": [{"molecule_name": "Vorinostat", "protein_target_name": "HDAC1, HDAC2, HDAC3, HDAC6", "binding_metric": "IC50", "value": "<86", "unit": "nM"}]}
{"raw_mentions": "There are no sentences that contain all four required components: a specific molecule name, ID or other identifier, a bioactivity metric (IC50, Ki, Kd, EC50 and their variations), a specific numeric value for that metric, and a unit for that value. The text appears to be a medical case study and does not include the required bioactivity metrics and values."}
{"raw_mentions": "There are no sentences that meet the specified criteria. The text does not contain any sentences with a specific molecule name, ID, or other identifier, a bioactivity metric (IC50, Ki, Kd, EC50, etc.), a specific numeric value for that metric, and a unit for that value."}
{"raw_mentions": "There are no sentences that meet the specified criteria. The text does not contain any sentences with a specific molecule name, ID, or other identifier, a bioactivity metric (IC50, Ki, Kd, EC50, etc.), a specific numeric value for that metric, and a unit for that value."}
